Innate Pharma SA IPHYF
Annual
Quarterly
No annual revenue total was found in Innate Pharma SA's SEC filings.
Innate Pharma SA (IPHA) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances).
Revenue
—
Net income
—
Operating cash flow
—
Free cash flow
—
EPS
—
Dividend per share
None
Shares outstanding
93.72M
+11.8% vs prior year
Net cash
—
Operating margin
—
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- IPHA (Nasdaq), IPHYF (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- France
- Headquarters
- Marseille
- SEC filer status
- Accelerated filer
- SEC CIK
- 1598599
- Former names
- Innate Pharma, SA (until Jan 31, 2014)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Oct 27, 2026 | Oct 27, 2026 |
| 6-K | Current report (foreign issuer) | Oct 21, 2026 | Oct 21, 2026 |
| 6-K | Current report (foreign issuer) | Oct 20, 2026 | Oct 20, 2026 |
| 6-K | Current report (foreign issuer) | Sep 17, 2026 | Sep 17, 2026 |
| 6-K | Current report (foreign issuer) | Sep 17, 2026 | Jun 30, 2026 |
| 6-K | Current report (foreign issuer) | Sep 17, 2026 | Sep 16, 2026 |
All 338 Innate Pharma SA SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.